Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -19.85% is 28% above its 5-year average of -27.48%, near the high end of its 5-year range (-42.34%–-16.35%).
As of the fiscal period ended Tuesday, June 30, 2026. 16.98% above its 12-month average of -23.91%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -19.85%.
RETURN ON EQUITY (ROE)
-19.85%
RETURN ON EQUITY (ROE) AVG TTM
-23.91%
RETURN ON EQUITY (ROE) AVG 3Y
-27.41%
RETURN ON EQUITY (ROE) AVG 5Y
-27.48%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+16.98%
CURRENT VS 3Y AVG
+27.55%
CURRENT VS 5Y AVG
+27.74%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
+52.74%
vs the sector median at left
Kymera Therapeutics, Inc.
Market Cap
$8.72B
Return on Equity (ROE)
-19.85%
TTM Avg
-23.91%
3Y Avg
-27.41%
5Y Avg
-27.48%
Market Cap
$8.67B
Return on Equity (ROE)
-68.73%
TTM Avg
-161.81%
3Y Avg
-110.86%
5Y Avg
-82.70%
Market Cap
$8.92B
Return on Equity (ROE)
9.85%
TTM Avg
9.79%
3Y Avg
-15.74%
5Y Avg
-21.41%
Market Cap
$8.93B
Return on Equity (ROE)
-2.97%
TTM Avg
3.00%
3Y Avg
15.91%
5Y Avg
17.66%
Market Cap
$8.97B
Return on Equity (ROE)
-230.05%
TTM Avg
-355.61%
3Y Avg
-251.82%
5Y Avg
-322.00%
Market Cap
$8.38B
Return on Equity (ROE)
26.84%
TTM Avg
-21.41%
3Y Avg
-36.14%
5Y Avg
-25.75%
Market Cap
$9.21B
Return on Equity (ROE)
-2.97%
TTM Avg
3.00%
3Y Avg
15.91%
5Y Avg
17.66%
Market Cap
$9.33B
Return on Equity (ROE)
26.39%
TTM Avg
25.41%
3Y Avg
19.99%
5Y Avg
14.02%
Market Cap
$7.99B
Return on Equity (ROE)
73.08%
TTM Avg
39.77%
3Y Avg
-73.65%
5Y Avg
-82.53%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | $8.72B | -19.85% | -23.91% | -27.41% | -27.48% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.67B | -68.73% | -161.81% | -110.86% | -82.70% |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.92B | 9.85% | 9.79% | -15.74% | -21.41% |
| Bruker Corporation (BRKRP)vs › | $8.93B | -2.97% | 3.00% | 15.91% | 17.66% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.97B | -230.05% | -355.61% | -251.82% | -322.00% |
| Oscar Health, Inc. (OSCR)vs › | $8.38B | 26.84% | -21.41% | -36.14% | -25.75% |
| Bruker Corporation (BRKR)vs › | $9.21B | -2.97% | 3.00% | 15.91% | 17.66% |
| Insulet Corp. (PODD)vs › | $9.33B | 26.39% | 25.41% | 19.99% | 14.02% |
| TG Therapeutics, Inc. (TGTX)vs › | $7.99B | 73.08% | 39.77% | -73.65% | -82.53% |
| Vaxcyte, Inc. (PCVX)vs › | $9.61B | -38.59% | -21.29% | -24.61% | -26.58% |
ROE
-19.9%
ROA
-18.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -19.85% |
| 2026-03-31 | -20.46% |
| 2025-12-31 | -19.71% |
| 2025-09-30 | -31.19% |
| 2025-06-30 | -28.35% |
| 2025-03-31 | -30.64% |
| 2024-12-31 | -26.79% |
| 2024-09-30 | -18.76% |
| 2024-06-30 | -23.05% |
| 2024-03-31 | -21.74% |
| 2023-12-31 | -37.21% |
| 2023-09-30 | -42.34% |
| 2023-06-30 | -36.19% |
| 2023-03-31 | -34.43% |
| 2022-12-31 | -31.58% |
| 2022-09-30 | -30.00% |
| 2022-06-30 | -35.04% |
| 2022-03-31 | -28.88% |
| 2021-12-31 | -21.80% |
| 2021-09-30 | -16.35% |
| 2021-06-30 | -22.63% |
| 2021-03-31 | -17.34% |
| 2020-12-31 | -16.06% |
| 2020-09-30 | -15.07% |
| 2020-06-30 | -45.99% |
